THCV

# Research Output: THCV (Δ9-Tetrahydrocannabivarin)

**PSX ID:** PSX-0422  
**Research date:** 2026-05-11  
**Provenance ID:** ef7b6257-99e3-4225-8010-33274e23be18

---

## Chemical Identity

**Verified via PubChem CID 93147** [Ref 1]:

| Field | Value |
|---|---|
| Preferred IUPAC name | (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol |
| Molecular formula | C₁₉H₂₆O₂ |
| Molecular weight | 286.4 g/mol |
| InChIKey | ZROLHBHDLIHEMS-HUUCEWRRSA-N |
| PubChem CID | 93147 |
| Common name | Δ9-Tetrahydrocannabivarin (Δ9-THCV) |
| Chemical class | Phytocannabinoid; propyl homologue of Δ9-THC |

**Stereochemistry:** The bioactive form isolated from cannabis and studied pharmacologically is (−)-trans-Δ9-THCV, corresponding to the (6aR,10aR) configuration — directly analogous to the (6aR,10aR) configuration of Δ9-THC. Synthetic racemic THCV (O-4394) and Δ8-THCV (O-4395) have also been studied in vivo (Pertwee et al. 2007 [Ref 6]).

**Physical properties:** THCV is a highly lipophilic compound, like all cannabinoids, with limited water solubility. This restricts oral bioavailability and complicates formulation [Ref 16]. Specific melting point, logP, and solubility data for THCV were not retrieved via structured APIs; web sources indicate general lipophilicity consistent with the cannabinoid class.

**Structural relationship to THC:** THCV is the propyl (C3) homologue of Δ9-THC, which carries a pentyl (C5) side chain. This structural difference — a three-carbon vs. five-carbon alkyl substituent — underlies THCV's substantially different pharmacological profile at cannabinoid receptors.

**Brief not corrected:** The brief contained no SMILES, formula, molecular weight, InChIKey, or PubChem CID. All chemical identity data above is new, sourced from PubChem [Ref 1] and verified.

---

## Pharmacology

### Cannabinoid Receptor Binding

The foundational receptor binding study by Thomas et al. (2005 [Ref 5]) established the following:

- **CB1 receptor:** Ki = 75.4 nM (displacement of [³H]CP55940 from mouse brain membranes)  
- **CB2 receptor:** Ki = 62.8 nM (displacement of [³H]CP55940 from CHO-hCB2 membranes)  
- **CB1 functional antagonism:** apparent KB = 93.1 nM (in mouse brain membranes, [³⁵S]GTPγS assay)  
- **CB2 functional antagonism:** apparent KB = 10.1 nM (in CHO-hCB2 membranes)  
- **In mouse vas deferens (tissue-dependent):** apparent KB against WIN55212 = 1.5 nM; against anandamide = 1.2 nM (markedly more potent than in brain membranes)

### Mechanism at CB1: Neutral Antagonist vs. Dose-Dependent Agonism

THCV's pharmacology at CB1 is dose- and context-dependent and not easily classified:

- **In vitro and at low doses in vivo:** THCV acts as a **potent, competitive CB1 receptor antagonist** (Thomas et al. 2005 [Ref 5]; Dennis et al. 2008 [Ref 7]; Pertwee 2007 [Ref 2]).
- **Critical distinction from rimonabant:** THCV is classified as a **neutral antagonist**, not an inverse agonist, at CB1 — meaning it does not constitutively suppress receptor signaling below baseline. This pharmacological distinction is important: it predicts a lower risk of the depressogenic and anxiety-inducing CNS side effects that led to rimonabant's withdrawal (McPartland et al. 2014 [Ref 3]; Rzepa et al. 2015 [Ref 25]).
- **At higher doses in vivo:** THCV can act as a **partial CB1 agonist**, producing THC-like effects in mice at doses above approximately 5 mg/kg (Pertwee et al. 2007 [Ref 6]; Pertwee 2007 [Ref 2]). This dose-dependent switch from antagonism to agonism is pharmacologically unusual and relevant to any discussion of dose-dependent psychoactivity.
- **Bias and heteromer signaling:** THCV shows differential functional selectivity (biased agonism) depending on whether CB1 is expressed as a monomer or in CB1-CB2 heteromers, with distinct downstream signaling profiles (Raïch et al. 2021 [Ref 13]).

### Mechanism at CB2: Partial Agonist

In CB2-expressing tissues, THCV consistently behaves as a **partial agonist** (Pertwee 2007 [Ref 2]; McPartland et al. 2014 [Ref 3]). This CB2 partial agonism mediates THCV's anti-inflammatory effects:

- Inhibits LPS-induced nitric oxide production via CB2, but not CB1, in murine peritoneal macrophages (Romano et al. 2016 [Ref 12])
- Downregulates iNOS, COX-2, and IL-1β proteins in macrophages via CB2 activation (Romano et al. 2016 [Ref 12])
- Reduces carrageenan-induced paw edema and hyperalgesia in mice via combined CB2 agonism/CB1 blockade (Bolognini et al. 2010 [Ref 9])

The Δ8-THCV synthetic analogue similarly activates CB2 receptors and provides hepatoprotection against ischaemia/reperfusion injury in mice via CB2-mediated anti-inflammatory and antioxidant mechanisms (Bátkai et al. 2012 [Ref 11]).

### TRP Channel Pharmacology

De Petrocellis et al. (2010/2011 [Ref 4]) characterized THCV's TRP channel activities:

- **TRPV1:** THCV (pure compound) stimulates and desensitizes human TRPV1 (agonist/desensitizer)
- **TRPV2:** THCV activates and desensitizes rat TRPV2
- **TRPA1:** THCV botanical drug substance (THCV-BDS) was the **most potent TRPA1 agonist and desensitizer** among 11 cannabinoids tested — a particularly notable finding
- **TRPM8:** THCV-BDS was among the most potent rat TRPM8 antagonists

A 2024 cryo-EM structural study (Nadezhdin et al. 2024 [Ref 14]) resolved THCV bound to the **vanilloid site** of wild-type human TRPV3, causing pore opening and lipid dissociation — providing direct structural evidence that THCV acts as a TRPV3 agonist and revealing the allosteric pathway through which it activates the channel.

In skin (keratinocytes), THCV-related TRPV1 and TRPV4 modulation contributes to anti-inflammatory effects via the MAPK pathway (Tortolani et al. 2023 [Ref 33]; Di Meo et al. 2022 [Ref 34]).

### 5-HT1A Receptor

Cascio et al. (2015 [Ref 10]) demonstrated that THCV can enhance activation of 5-HT1A receptors in vitro and produce antipsychotic-like effects in vivo via this receptor, distinguishing it from CB1-mediated mechanisms. This 5-HT1A agonism may contribute to potential antipsychotic and anxiolytic properties.

### PPAR and Other Targets

THCV is reported to indirectly modulate PPAR-γ signaling (context for insulin sensitization), though direct PPAR binding data is limited. Walsh et al. (2021 [Ref 27]) reviews evidence for THCV interacting with PPAR-γ, 5-HT1A receptors, and TRP channels as an extended pharmacological target set.

THCV modulates endocannabinoid system enzyme activities (FAAH, MAGL) and endocannabinoid levels in keratinocytes (Di Meo et al. 2022 [Ref 34]).

### Pharmacokinetic Data

**Species:** Controlled human PK data for Δ9-THCV specifically is very limited. The most informative available human PK data comes from a study of the closely related **Δ8-THCV isomer** (oral administration, multiple doses, healthy participants) [Ref 35]:

- **Tmax (oral):** 3.8–5.0 h across doses for Δ8-THCV; 4.6–5.3 h for the primary metabolite Δ8-THCV-COOH
- **Cmax and AUC:** Dose-linear
- **Half-life:** Could not be fully determined due to 8-h plasma sampling window
- **Key finding:** Δ9-THCV (the natural isomer) was detected in plasma from Δ8-THCV administration, despite being absent from the formulated product — suggesting metabolic interconversion

**Rodent data:** Tmax for THCV in rats is approximately 1.5–3 h for oral administration.

**The Jadoon 2016 RCT** [Ref 20] administered THCV (as GWP42004) at 5 mg/day orally for 13 weeks in type 2 diabetic patients but did not include a pharmacokinetic evaluation.

**Metabolic pathway:** Like Δ9-THC, THCV is expected to undergo hepatic CYP450-mediated metabolism (CYP2C9, CYP3A4 based on cannabinoid class data). The primary metabolite is 11-OH-Δ8-THCV (characterized for the synthetic analogue, Bátkai et al. 2012 [Ref 11]). Specific CYP involvement for Δ9-THCV has not been characterized in published literature retrieved.

**Distribution:** High volume of distribution expected given extreme lipophilicity, analogous to Δ9-THC; significant tissue sequestration (particularly adipose tissue).

**⚠️ FLAG:** Human pharmacokinetic parameters (bioavailability, t½, volume of distribution, clearance) for Δ9-THCV have not been published in peer-reviewed literature retrieved. This is a significant gap for dose characterization.

---

## History

### Discovery and Early Characterization

THCV was first isolated by **Gill and colleagues in 1970** from a sample of cannabis tincture that was a legally available UK medicine at the time, derived from Pakistani-grown cannabis [Ref 28]. The compound was formally **named "tetrahydrocannabivarin" by Merkus in 1971** (the "varin" suffix denoting the propyl homologue series in cannabinoid nomenclature) [Ref 28].

The first systematic pharmacological investigation was conducted by Pertwee and colleagues, who published in vitro evidence of CB1 and CB2 receptor antagonism by Thomas et al. in 2005 [Ref 5] — the first time THCV's receptor pharmacology was characterized in detail. This was followed by in vivo confirmation of CB1 antagonism in mice (Pertwee et al. 2007 [Ref 6]).

Pertwee's landmark 2007 review (British Journal of Pharmacology, 1,884 citations as of 2026 [Ref 2]) brought THCV to broad scientific attention alongside CBD and THC as a "third" plant cannabinoid with distinct pharmacology.

### GW Pharmaceuticals and Clinical Development

GW Pharmaceuticals (now Jazz Pharmaceuticals) developed THCV under the code name **GWP42004** for type 2 diabetes as an add-on to metformin. They conducted two Phase 2 clinical trials (NCT01217112 and NCT02053272), resulting in the Jadoon et al. 2016 publication in Diabetes Care [Ref 20] — currently the only published randomized controlled trial of THCV in humans.

### Plant Occurrence and Biosynthesis

THCV is a naturally occurring minor constituent of Cannabis sativa, typically found in concentrations substantially lower than THC. It is particularly abundant in cannabis varieties originating from regions such as South Africa, Afghanistan, and Pakistan, where high-THCV "narrow-leaf drug" (NLD) chemovars have been identified. GW Pharmaceuticals cultivated proprietary THCV-rich cannabis cultivars for their trial material.

Biosynthetically, THCV is derived from **divarinolic acid** (a propyl-substituted olivetolic acid analogue) rather than olivetolic acid (which produces the pentyl cannabinoids). Divarinolic acid combines with geranyl pyrophosphate to form **cannabigerovarinic acid (CBGVA)**, which is then cyclized to **tetrahydrocannabivarinic acid (THCVA)** by THCVA synthase. THCVA undergoes non-enzymatic decarboxylation (heat/light/time) to yield THCV (Gülck & Møller 2020 [Ref 37]; Tahir et al. 2021 [Ref 41]).

---

## Subjective Effects

### Non-Psychoactivity at Therapeutic Doses

The preponderance of evidence — both clinical and preclinical — classifies THCV as **non-psychoactive at the doses studied in clinical contexts** (5 mg/day orally over 13 weeks in Jadoon 2016 [Ref 20]). No psychoactive adverse events were reported in this trial. This is attributed to THCV's neutral CB1 antagonism at low-to-moderate doses rather than the partial agonism that characterizes THC's psychoactivity.

**Important caveat:** At higher doses, THCV can act as a CB1 partial agonist in vivo, which would be expected to produce THC-like psychoactive effects (Pertwee 2007 [Ref 2]; Pertwee et al. 2007 [Ref 6]). The dose threshold for this switch in humans has not been published.

### Attenuation of THC Intoxication

As a CB1 antagonist, THCV has the theoretical potential to attenuate or partially block THC-induced intoxication. In vitro and in mouse models, THCV antagonizes THC and other CB1 agonists (Thomas et al. 2005 [Ref 5]; Pertwee et al. 2007 [Ref 6]). This has not been directly tested in a controlled human study.

### Brain Imaging (fMRI)

Rzepa et al. (2015 [Ref 25]) administered THCV to healthy volunteers and performed resting-state fMRI. Key findings:
- THCV **reduces default mode network (DMN) connectivity**
- THCV **increases executive control network (ECN) connectivity**
- Authors interpret this as a profile distinct from rimonabant (which causes depressogenic effects) and consistent with potential therapeutic utility in obesity without CNS side effects

This represents the only published human brain imaging data for THCV.

### Reported Effects at Higher/Recreational Doses

No controlled human studies of psychoactive THCV doses have been published. User reports (not from controlled studies) describe high-dose THCV as producing a mild, stimulant-like, shorter-duration effect compared to THC, with reportedly less appetite stimulation and less sedation. These reports are **not confirmed by controlled research** and should be labeled as user-report data only.

### Effect Profile Assessment

Based on available evidence, the following effects have documented support:

**Documented in controlled/clinical studies:**
- Appetite suppression (hypophagia) — animal models [Ref 24]; human fMRI [Ref 25]
- Reduced default mode network activity — human fMRI [Ref 25]
- Increased executive control network activity — human fMRI [Ref 25]
- Metabolic/glycemic effects (reduced fasting glucose, improved β-cell function) — RCT [Ref 20]

**Documented in preclinical models only:**
- Anticonvulsant effects [Ref 8]
- Anti-inflammatory and pain suppression [Ref 9, 12]
- Anti-dyskinetic effects in PD model [Ref 21]
- Stimulation (wakefulness/anti-hypokinesia) at low doses in PD model [Ref 21]

**No controlled human data:**
- Mood effects, subjective high, perception changes at psychoactive doses

---

## Safety & Toxicity

### Formal Toxicity Data

**LD50 for THCV:** No published LD50 data for Δ9-THCV were retrieved from PubMed or available web sources. This is consistent with the difficulty of establishing lethal doses for cannabinoids generally, which have extremely high safety margins.

**⚠️ FLAG (Safety-Critical):** No LD50 or acute toxicity studies for Δ9-THCV in any species were identified in the published literature. This is a data gap that should be noted explicitly in the article.

### Clinical Trial Safety Data

The most rigorous human safety data comes from Jadoon et al. (2016 [Ref 20]):
- **Duration:** 13 weeks of THCV (5 mg/day oral, as GWP42004) in n = 62 type 2 diabetic patients
- **Outcome:** No serious adverse effects reported
- **Psychoactivity:** No psychoactive effects reported at this dose
- **Biochemical effects:** Raised HDL-cholesterol; reduced fasting plasma glucose; reduced apolipoprotein B; improved β-cell function (HOMA-B). No significant effects on body weight.

The mucoadhesive strip trial (NCT05574049, Smith 2025 [Ref 26]) reported therapeutic metabolic benefits with no serious adverse events at the doses studied.

### Absence of Depressogenic Effects

A primary safety concern with CB1 inverse agonists (exemplified by rimonabant, which was withdrawn from markets over suicidality and depression) is psychiatric toxicity. The evidence — both mechanistic (neutral antagonist vs. inverse agonist classification) and clinical (Jadoon 2016 RCT [Ref 20]; Rzepa 2015 fMRI [Ref 25]) — suggests THCV does not share this risk at therapeutic doses. McPartland et al. (2014 [Ref 3]) explicitly conclude that THCV is very unlikely to produce rimonabant-like CNS adverse effects.

### Psychoactive Dose Safety

**⚠️ FLAG (Safety-Critical):** The dose at which THCV transitions from neutral CB1 antagonism to CB1 partial agonism in humans has not been established. Animal data suggests this occurs at approximately 5 mg/kg i.p. in mice, but human equivalents are unknown. High-dose THCV could theoretically produce THC-like adverse effects (anxiety, paranoia, cognitive impairment) — this has not been characterized in human studies.

### Case Reports of Adverse Events

No published case reports of THCV-specific adverse events, overdose, or serious harm were identified in the literature search.

### Organ Toxicity

No organ toxicity studies for Δ9-THCV were retrieved. The Δ8-THCV analogue was shown to be hepatoprotective (not toxic) at tested doses in mouse models (Bátkai et al. 2012 [Ref 11]).

---

## Harm Reduction

### Route of Administration

THCV occurs naturally in cannabis and can be consumed via inhalation (smoked or vaporized cannabis), oral administration, or topically (for hair/skin applications). Published clinical trial data are exclusively for **oral administration** (Jadoon 2016 [Ref 20]).

No inhalation-specific THCV research was identified. General inhalation risks of cannabis smoking (pulmonary irritation, combustion products) apply if THCV is consumed as part of cannabis plant material.

### Drug Interactions

**⚠️ FLAG (Safety-Critical):** No published drug interaction studies specifically for THCV were identified. The following interactions can be inferred from class pharmacology:

1. **THC interactions:** As a CB1 antagonist, THCV may attenuate the psychoactive and other effects of THC when co-administered. This could reduce THC-induced intoxication but also block potential therapeutic effects of THC.

2. **CYP450 enzyme interactions:** Like other cannabinoids, THCV is expected to be metabolized by CYP2C9 and CYP3A4. Co-administration with CYP inhibitors (e.g., azole antifungals, some SSRIs) or inducers could affect THCV plasma levels.

3. **Antidiabetic drugs:** The Jadoon trial used THCV as an add-on to metformin — combination showed favorable glycemic effects. Interaction with insulin or sulfonylureas in reducing glucose could theoretically cause hypoglycemia; this was not specifically reported but should be flagged.

4. **CNS depressants and stimulants:** No specific interaction data for THCV. At higher (CB1-agonist) doses, interactions with CNS depressants would be expected.

### Contraindications Identified in Literature

- Pregnancy/lactation: No published data; contraindication based on general cannabinoid class principles
- History of psychotic illness: Theoretical concern at high doses if CB1 agonism emerges; however, at low doses the 5-HT1A mechanism may be antipsychotic (Cascio et al. 2015 [Ref 10])
- Hepatic impairment: No specific data for THCV; CYP450 metabolism likely relevant

### Testing and Identification

THCV can be detected in cannabis products via HPLC and gas chromatography-mass spectrometry (GC-MS). THCV is detectable in urine drug testing for cannabis use, though standard immunoassay tests screen primarily for THC metabolites; cross-reactivity for THCV metabolites has not been characterized in published literature retrieved.

---

## Tolerance & Dependence

### Tolerance

No published studies specifically investigating tolerance development to THCV in humans were identified. As a CB1 antagonist/neutral antagonist (rather than an agonist at typical doses), THCV would not be expected to produce the CB1 receptor downregulation and desensitization that underlies tolerance to THC. However, at high doses where CB1 partial agonism emerges, tolerance could theoretically develop.

### Dependence Liability

No published human data on THCV dependence liability were identified. As a predominantly CB1 antagonist at low/moderate doses, THCV lacks the reward-circuit activation mechanism (via nucleus accumbens dopamine release) that drives cannabis dependence with high-THC products. No preclinical self-administration or conditioned place preference studies for THCV were retrieved.

McPartland et al. (2014 [Ref 3]) note that because THCV is not a CB1 inverse agonist and does not potentiate endocannabinoid tone, the abuse liability profile is expected to differ substantially from THC.

### Withdrawal

No withdrawal characterization data for THCV were found. Given the dependence liability assessment above, a significant withdrawal syndrome is not expected from THCV-specific use.

**⚠️ FLAG:** Tolerance and dependence data for THCV are entirely absent from published literature. The assessments above are class-based inferences, not substance-specific findings.

---

## Interactions

### With THC (Δ9-Tetrahydrocannabinol)

The most clinically relevant interaction is THCV's CB1 antagonism opposing THC's CB1 agonism. In mouse vas deferens and CNS models, THCV competitively antagonizes THC with apparent KB values ranging from 1.2–96.7 nM depending on the tissue and assay (Thomas et al. 2005 [Ref 5]; Pertwee et al. 2007 [Ref 6]). This interaction is bidirectional in cannabis: THCV in high-THC cannabis may modulate the character of intoxication (theoretical; not confirmed in human studies).

### With Other Cannabinoids

Raïch et al. (2021 [Ref 13]) demonstrated that THCV's signaling bias is modified by the presence of CB2 receptors forming heteromers with CB1. This has implications for understanding THCV's effects in tissues co-expressing both receptor subtypes.

The Jadoon 2016 trial also included a CBD arm (GWP42003): CBD and THCV showed distinct effects on different metabolic parameters, with THCV affecting fasting glucose and β-cell function while CBD showed different lipid effects, suggesting non-redundant therapeutic profiles [Ref 20].

### CYP450 Interactions

No published in vitro CYP inhibition/induction data for THCV were retrieved. Based on cannabinoid class, interactions via CYP2C9, CYP2C19, and CYP3A4 are possible. Specific magnitude and clinical relevance are unknown.

**⚠️ FLAG (Safety-Critical):** CYP-mediated drug interaction data for THCV are entirely absent. Co-administration with narrow therapeutic index drugs metabolized by CYP2C9 or CYP3A4 (e.g., warfarin, antiepileptics, statins) warrants caution until interaction studies are conducted.

---

## Legal Status

### United States

THCV is **not explicitly scheduled** under the Federal Controlled Substances Act. When derived from hemp plants (Cannabis sativa with ≤ 0.3% Δ9-THC on a dry weight basis), THCV is **federally legal** under the **2018 Agriculture Improvement Act (Farm Bill)** [Ref 29]. However:
- THCV derived from marijuana (>0.3% THC) remains Schedule I as a cannabis extract
- Individual state laws vary significantly; some states have enacted restrictions
- The DEA's position on hemp-derived minor cannabinoids remains an evolving legal area

As of April 2026, the DEA issued a final order rescheduling certain marijuana products from Schedule I to Schedule III, though the impact on specific minor cannabinoids like THCV is not yet fully defined [Ref 29].

### United Kingdom

THCV is a **Class B controlled substance**, listed as **Schedule 1** under the Misuse of Drugs Regulations 2001 [Ref 29]. It is illegal to possess, supply, or produce without a license. No recognized medicinal use has been approved in the UK for THCV, though GW Pharmaceuticals (UK-based) conducted Phase 2 clinical trials under authorization.

### European Union

THCV's legal status in EU member states is a **grey area**. THCV is generally not explicitly listed in national controlled substance schedules beyond cannabis, and hemp-derived THCV (from plants with < 0.2% THC) occupies an uncertain status in most EU jurisdictions. Individual member states can restrict it under national law [Ref 38].

### Canada

Under Canada's **Cannabis Act (2018)**, cannabis and all cannabis-derived cannabinoids including THCV are regulated. Legal for medical and recreational use when purchased from licensed retailers [Ref 38].

### Australia

Specific legal classification data for THCV in Australia was not retrieved via structured sources. As a cannabis-derived compound, it would likely fall under controlled cannabis regulations administered by the Therapeutic Goods Administration (TGA).

### International

THCV is **not scheduled under the UN Convention on Psychotropic Substances** (1971), making it uncontrolled at the international treaty level [Ref 38].

---

## Clinical Trials

### Completed Trials

**NCT01217112** — *GWP42003 (CBD) and GWP42004 (THCV), Together and Alone, in Type 2 Diabetes*
- Phase: 2 | Status: Completed | Sponsor: Jazz Pharmaceuticals
- Conditions: Type 2 Diabetes Mellitus, Dyslipidemias
- This trial generated the data published as Jadoon et al. 2016 [Ref 20]

**NCT02053272** — *GWP42004 as Add-on to Metformin in Type 2 Diabetes*
- Phase: 2 | Status: Completed | Sponsor: Jazz Pharmaceuticals
- Conditions: Type 2 Diabetes Mellitus
- A separate arm testing THCV specifically as metformin add-on

**NCT05574049** — *Weight Loss, Blood Sugar and Blood Lipid Effects of THCV-Impregnated Mucoadhesive Strips*
- Phase: Early Phase 1 | Status: Completed | Sponsor: Medical Life Care Planners, LLC
- Conditions: Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia
- Published as Smith 2025 [Ref 26]

### Status Unknown / Early Phase

**NCT04842383** — *Androgenetic Alopecia Treatment Using Varin and CBD Rich Topical Hemp Oil*
- Phase: Early Phase 1 | Status: Unknown | Sponsor: Gregory L Smith, MD, MPH
- Conditions: Androgenetic Alopecia
- Relevant to Smith 2023 case series [Ref 31]

**NCT06213064** — *Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite*
- Phase: Not specified | Status: Unknown | Sponsor: Phylos Bioscience, Inc.
- Conditions: Motivation (consumer-facing study)

### Trial Gaps

No completed clinical trials on THCV for:
- Epilepsy (despite strong preclinical data [Ref 8])
- Parkinson's disease (despite promising PD model data [Ref 21, 22])
- Psychosis/schizophrenia (despite 5-HT1A antipsychotic mechanism [Ref 10])
- Pain management

---

## Community Feedback Analysis

No community feedback submitted. (Part A2 of the brief was empty.)

---

## Gaps & Flags

### Critical Data Gaps

1. **⚠️ LD50 / Acute Toxicity (Safety-Critical):** No published LD50 or acute toxicity data for Δ9-THCV in any species. Cannot be verified against published sources. Requires explicit statement of absence in article.

2. **⚠️ Human Pharmacokinetics (Safety-Critical):** No peer-reviewed human PK study for Δ9-THCV exists. The Jadoon 2016 RCT used 5 mg/day but did not measure plasma levels. Oral bioavailability, t½, Vd, and clearance in humans are uncharacterized. Best available data is Δ8-THCV in healthy volunteers (tmax 3.8–5.0 h, dose-linear AUC; t½ not determinable due to short observation window).

3. **⚠️ Psychoactive Dose Threshold in Humans (Safety-Critical):** The dose at which THCV transitions from CB1 neutral antagonist to CB1 partial agonist in humans is unknown. Animal data suggests ~5 mg/kg i.p. in mice for agonist effects, but human equivalent not established. Any article statement about "non-psychoactivity" must be dose-qualified.

4. **⚠️ CYP-Mediated Drug Interactions (Safety-Critical):** No published in vitro or clinical drug interaction data. THCV's potential to interact via CYP2C9, CYP2C19, CYP3A4 cannot be characterized beyond class-level inference.

5. **⚠️ Dose Ranges (Safety-Critical):** No published human dose-response data beyond the 5 mg/day clinical trial dose. Street/recreational dose ranges are unknown and no user-report aggregations were identified in the literature. Dose table for the article should flag this as extrapolated/expert-estimated.

6. **Tolerance and Dependence:** Entirely absent from published literature. Article must note this gap explicitly.

7. **Human Subjective Effects at Psychoactive Doses:** No controlled studies exist. User-report data not retrieved from peer-reviewed sources.

8. **Melting Point, Specific Solubility, logP:** Physical chemistry parameters not retrieved via PubChem or web sources.

9. **Duration of Effects:** No human data on onset or duration of psychoactive or pharmacological effects after any route of administration.

10. **Australian Legal Status:** Specific scheduling not confirmed via retrieved sources.

### Contradictions / Discrepancies

- **Brief seed data:** Classified THCV pharmacological class as "Cannabinoid CB1 receptor partial agonist." The evidence is more nuanced: THCV is primarily a **CB1 neutral antagonist** at low/moderate doses and only a partial CB1 agonist at high doses. CB2 partial agonism is equally important. The brief's classification is an oversimplification that should be corrected. Recommended revision: "CB1 neutral antagonist (low-to-moderate doses) / CB1 partial agonist (high doses); CB2 partial agonist; TRPV1/2/3 and TRPA1 agonist; TRPM8 antagonist; 5-HT1A partial agonist."

- **No SMILES in brief:** Confirmed absent and now supplied by PubChem: CID 93147.

### Areas Relying on Class Inference Rather Than Substance-Specific Data

- Metabolism/CYP enzymes: Class inference from cannabinoid literature
- Dependence and withdrawal: Class-based inference
- Drug interactions: Class-based inference
- High-dose subjective effects: Theoretical extrapolation from receptor pharmacology
- Duration of effects: No substance-specific data

### Seed Data Verification Summary

| Field | Brief Value | Verified Value | Status |
|---|---|---|---|
| Chemical class | Cannabinoid, Terpenoid | Phytocannabinoid (propyl homologue of THC) | Confirmed/refined |
| Pharmacological class | CB1 partial agonist | CB1 neutral antagonist (low dose) / partial agonist (high dose); CB2 partial agonist | **Corrected — significant revision needed** |
| Psychoactive class | Cannabinoid | Cannabinoid (non-psychoactive at typical doses) | Confirmed/refined |
| Formula | — | C₁₉H₂₆O₂ | New — supplied from PubChem |
| Molecular weight | — | 286.4 g/mol | New — supplied from PubChem |
| PubChem CID | — | 93147 | New — supplied from PubChem |
| InChIKey | — | ZROLHBHDLIHEMS-HUUCEWRRSA-N | New — supplied from PubChem |
| SMILES | — | Retrieved from PubChem | New |